391 related articles for article (PubMed ID: 15558796)
1. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
[TBL] [Abstract][Full Text] [Related]
3. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
5. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
6. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
8. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
[TBL] [Abstract][Full Text] [Related]
9. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma.
Zablotska LB; Neugut AI
Cancer; 2003 Mar; 97(6):1404-11. PubMed ID: 12627503
[TBL] [Abstract][Full Text] [Related]
10. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
Armes JE; Egan AJ; Southey MC; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer; 1998 Dec; 83(11):2335-45. PubMed ID: 9840533
[TBL] [Abstract][Full Text] [Related]
11. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
12. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma.
Kroman N; Holtveg H; Wohlfahrt J; Jensen MB; Mouridsen HT; Blichert-Toft M; Melbye M
Cancer; 2004 Feb; 100(4):688-93. PubMed ID: 14770422
[TBL] [Abstract][Full Text] [Related]
13. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
15. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
[TBL] [Abstract][Full Text] [Related]
16. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
17. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
18. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
